Barclays upgrades Intuitive Surgical stock to Strong Buy

Published on 10/09/2026 at 16:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue hit USD 2.89 billion, up 18.40 percent year over year. Intuitive Surgical stock costs EUR 380.73 on October 9, 2026 after EUR 369.88.

Key points in brief

Barclays upgraded Intuitive Surgical to Strong Buy on October 8, 2026.
Second-quarter revenue reached USD 2.89 billion, up 18.40 percent year over year.
Intuitive Surgical stock was trading at EUR 380.73 at Lang & Schwarz on October 9, 2026, plus 2.93 percent versus the prior close.
The next quarterly report is scheduled for October 20, 2026.

Extreme Makrofotografie einer miniaturisierten chirurgischen Roboterarmspitze mit Nadelhalter-Handgelenk, feinen Kabelzügen und präzisionsgefrästen Titangelenken, flache Schärfentiefe, metallisch-blaue Töne — Intuitive Surgical US46120E6023 Makroaufnahme zeigt miniaturisierten Roboter Endeffektor mit präziser feiner Gelenkmechanik, Illustration mit AI erstellt.

Intuitive Surgical (ISIN US46120E6023) was trading at EUR 380.73 at Lang & Schwarz on October 9, 2026 at 4:17 p.m. CEST, up 2.93 percent versus the prior close of EUR 369.88. According to MarketBeat on October 8, 2026, Barclays upgraded the company to Strong Buy.

Barclays joins a constructive backdrop

MarketBeat reported that the broader analyst consensus was Moderate Buy, based on 31 ratings, with an average price target of USD 502.53. The same report cited quarterly revenue of USD 2.89 billion and earnings per share of USD 2.80, compared with a USD 2.83 billion revenue estimate and USD 2.48 earnings-per-share estimate.

That combination gives the Barclays action a measurable operating backdrop. Revenue increased 18.40 percent year over year in the second quarter of 2026, while the average target remained materially above the USD 415.41 Nasdaq reference cited by the report.

Three milestones shaped the setup

On July 16, 2026, Intuitive Surgical reported second-quarter revenue of USD 2.89 billion and earnings per share of USD 2.80, according to MarketBeat. On September 8, 2026, the company published a meta-analysis covering more than 14 million procedures across 13 common benign conditions, as listed on its investor-relations page and detailed by Zacks.

On September 14, 2026, Intuitive announced a CE mark for transvaginal gynecologic procedures using da Vinci SP, described by EQS News as a world's-first indication for the platform. The approval expands the addressable use of the single-port system in European gynecologic surgery.

What does the next report test?

Intuitive's next earnings conference call is scheduled for October 20, 2026, according to the company's investor-relations calendar. The report will put the second-quarter growth rate beside the company's full-year procedure-growth range of 13.50 percent to 15.50 percent, a comparison that matters because the U.S. procedure trend has moderated.

The stock's valuation leaves execution central to the debate. Its Nasdaq 52-week range was USD 328.57 to USD 603.88 as of October 9, 2026, while the USD 149.8 billion market capitalization reflects the scale investors already assign to the robotic-surgery franchise.

Stock advances in Friday trading

Intuitive Surgical was trading at EUR 380.73 at Lang & Schwarz on October 9, 2026 at 4:17 p.m. CEST, plus 2.93 percent versus the Lang & Schwarz prior close of EUR 369.88. The further course of trading is shown by the continuously updated real-time quote of Intuitive Surgical stock.